Michael S Kraus1, Richard S E Keefe. 1. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina 27710, USA.
Abstract
BACKGROUND: Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning. AIMS: To critically examine a selection of the most common batteries used to assess cognition in schizophrenia. METHOD: Literature review of cognitive assessment batteries for use in schizophrenia. RESULTS: A wide variety of neurocognitive test batteries have been developed or adapted to assess cognition in schizophrenia. These differ in time requirements, repeatability, ease of administration, degree of face validity, availability of co-normative data and degree to which results can be parsed into separate domains of cognitive functioning. The most appropriate depends on the setting and the question being addressed. CONCLUSIONS: Cognitive outcome measures have reshaped our understanding of schizophrenia and will be essential tools for unravelling the aetiology ofthe disease and designing more effective interventions.
BACKGROUND:Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning. AIMS: To critically examine a selection of the most common batteries used to assess cognition in schizophrenia. METHOD: Literature review of cognitive assessment batteries for use in schizophrenia. RESULTS: A wide variety of neurocognitive test batteries have been developed or adapted to assess cognition in schizophrenia. These differ in time requirements, repeatability, ease of administration, degree of face validity, availability of co-normative data and degree to which results can be parsed into separate domains of cognitive functioning. The most appropriate depends on the setting and the question being addressed. CONCLUSIONS: Cognitive outcome measures have reshaped our understanding of schizophrenia and will be essential tools for unravelling the aetiology ofthe disease and designing more effective interventions.
Authors: Anita J Bechtholt-Gompf; Hali V Walther; Martha A Adams; William A Carlezon; Dost Ongür; Bruce M Cohen Journal: Neuropsychopharmacology Date: 2010-06-09 Impact factor: 7.853
Authors: Xiang Yang Zhang; Da Chun Chen; Mei Hong Xiu; Colin N Haile; Xingguang Luo; Ke Xu; Hui Ping Zhang; Lingjun Zuo; Zhijun Zhang; Xiangrong Zhang; Therese A Kosten; Thomas R Kosten Journal: Hum Genet Date: 2012-02-24 Impact factor: 4.132
Authors: Alan S Brown; Sophia Vinogradov; William S Kremen; John H Poole; Yuanyuan Bao; David Kern; Ian W McKeague Journal: Psychiatry Res Date: 2011-05-19 Impact factor: 3.222
Authors: Junxia Tang; Robert P LeGros; Natalia Louneva; Lilly Yeh; Julia W Cohen; Chang-Gyu Hahn; Derek J Blake; Steven E Arnold; Konrad Talbot Journal: Hum Mol Genet Date: 2009-07-19 Impact factor: 6.150
Authors: Sreelatha S Narayanan; Triptish Bhatia; Dawn I Velligan; Vishwajit L Nimgaonkar; Smita N Deshpande Journal: Schizophr Res Date: 2015-10-31 Impact factor: 4.939